Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials
Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.
Publications
View AllAffiliated Researchers
Institution Info
- Type
- company
- Country
- US
- Publications
- 1
- Citations
- 0
External Links
Identifiers
- ROR
- https://ror.org/01reevc91